Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable
Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds
Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies
Avoiding Mediastinal Radiation Can Improve Patient Outcomes
Obese Men With Benign Biopsy At High Risk for Prostate Cancer
Ibrutinib Shows Disease Control In Elderly, High-Risk CLL Patients
Study Finds That CTC Was Used Correctly In Medicare Patients
ASCO Draft Recommendations Define Meaningful Trial Outcomes
Phase II Study Cohort Fails To Overcome Erlotinib Resistance
Alcohol Consumption Does Not Impact Survival of Breast Cancer
Study: Blood Test More Accurate Than Traditional Tumor Biopsy
European Treatment Regimen Less Toxic Than American Method
Study Finds Nearly Two-Thirds Of Children Return to Hospital Following Stem Cell Transplant
NCI CTEP Approved Trials For the Month of April
FDA Breakthrough Designation Granted to Pfizer’s Palbociclib
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”
